0001429260false0001429260us-gaap:CommonStockMember2025-06-172025-06-170001429260fbio:SeriesCumulativeRedeemablePerpetualPreferredStockMember2025-06-172025-06-1700014292602025-06-172025-06-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 17, 2025

Fortress Biotech, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
 (State or Other Jurisdiction
of Incorporation)

   

001-35366
 (Commission File Number)

    

20-5157386
(IRS Employer
Identification No.)

1111 Kane Concourse, Suite 301

Bay Harbor IslandsFL 33154

(Address of Principal Executive Offices)

(781652-4500

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

FBIO

Nasdaq Capital Market

9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

FBIOP

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 17, 2025, Fortress Biotech, Inc. (the “Company” or “Fortress”) held its annual meeting of stockholders (the “2025 Annual Meeting”) at 10:00 a.m. Eastern Time by means of an online virtual meeting platform.

 

At the 2025 Annual Meeting, the following five proposals were voted on by the stockholders: (i) the election of seven directors to hold office until the 2026 annual meeting of stockholders or until such director resigns or is removed from office; (ii) the ratification of the appointment of KPMG LLP as Fortress’s independent registered public accounting firm for the year ending December 31, 2025; (iii) an advisory vote to approve the compensation of Fortress’s named executive officers; (iv) an advisory vote on the frequency with which Fortress will hold an advisory vote on the compensation of Fortress’s named executive officers; and (v) the approval of the Second Amended and Restated Certificate of Incorporation to provide for, among other things, officer exculpation. The five proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the 2025 Annual Meeting filed with the Securities and Exchange Commission on April 28, 2025.

Proposal 1

 

The votes with respect to the election of seven directors to hold office until the 2026 annual meeting of stockholders were as follows:

 

Total Votes

Broker Non-

Director

Total Votes For

    

Against

    

Abstentions

    

Votes

Lindsay A. Rosenwald, M.D.

 

9,561,328

161,473

90,259

10,917,039

Jimmie Harvey, Jr., M.D.

 

9,510,319

199,781

102,960

10,917,039

Malcolm Hoenlein

 

9,439,773

270,268

103,019

10,917,039

Dov Klein, CPA

 

9,441,597

267,687

103,776

10,917,039

J. Jay Lobell

9,182,951

527,091

103,018

10,917,039

Kevin L. Lorenz, J.D.

9,510,472

199,584

103,004

10,917,039

Michael S. Weiss

9,528,675

193,499

90,886

10,917,039

Proposal 2

 

The vote with respect to the ratification of the selection of KPMG LLP as Fortress’s independent registered accounting firm for the year ending December 31, 2025 was as follows:

  

Total Votes For

Total Votes Against

Abstentions

20,400,173

314,490

15,436

Proposal 3

 

The advisory vote with respect to the approval of the compensation of Fortress’s named executive officers was as follows:

Total Votes For

Total Votes Against

Abstentions

Broker Non-Votes

9,388,005

312,265

112,790

10,917,039

Proposal 4

 

The advisory vote with respect to the frequency with which Fortress will hold an advisory vote on the compensation of Fortress’s named executive officers was as follows:

 

,051,405

One Year

Two Years

Three Years

Abstentions

2,051,405

183,953

7,421,176

156,526

In light of the vote on Proposal 4, the Board has determined that the Company will hold a Say-on-Pay vote every three years until the next required vote on the frequency of Say-on-Pay votes in 2031.

Proposal 5

 

The vote with respect to the approval of the Second Amended and Restated Certificate of Incorporation to provide for, among other things, officer exculpation, was as follows:

 

,

Total Votes For

Total Votes Against

Abstentions

Broker Non-Votes

7,964,484

1,723,623

124,953

10,917,039

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Fortress Biotech, Inc.

(Registrant)

Date: June 23, 2025

 

By:

/s/ David Jin

 

 

David Jin

 

 

Chief Financial Officer